Curosurf Suspension (Intratracheal)
Phospholipids
80mg/ml
Cheisi Farmaceutici S.p.A.
| Pack size | 1.5ml Vial |
|---|---|
| Dispensing mode | POM |
| Source | ITALY |
| Agent | NEW COUNTRY MEDICAL SUPPLIES |
| Retail Price | 981.00 AED |
Available as:
Indications
Curosurf Suspension (Intratracheal) is used for:
Resp distress syndrome (RDS) in premature infants.
Adult Dose
Child Dose
Prevention in premature infant <1250 g birthwt or w/ evidence of surfactant deficiency
Preferably w/in 15 mins of birth.
Rescue Preferably by 8 hr of age.
4 mL/kg birth wt(100 mg of phospholipids/kg birth wt) intratracheally up to 4 doses in 1st 48 hr.
Doses should not be given more frequently than 6 hrly. To be administered as soon as possible.
Renal Dose
Administration
Contra Indications
None known.
Precautions
Infants <600 g birth wt. For intratracheal use only.
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Phospholipids :
Transient bradycardia. O2 desaturation, endotracheal tube reflux & blockage, pallor, vasoconstriction, hypotension, HTN, hypocarbia, hypercarbia & apnea.
Mechanism of Action
Natural bovine pulmonary surfactant; replaces deficient endogenous lung surfactant in neonates with respiratory distress syndrome.
Surfactant prevents the alveoli from collapsing during expiration by lowering surface tension between alveolar surfaces and air.
Note
Curosurf 80mg/ml Suspension (Intratracheal) manufactured by Cheisi Farmaceutici S.p.A.. Its generic name is Phospholipids. Curosurf is availble in United Arab Emirates.
Farmaco UAE drug index information on Curosurf Suspension (Intratracheal) is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.